Zydus Cadila has received final approval from the United States Food
and Drug Administration (USFDA) to market Dimethyl Fumarate delayed
release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg,
Zydus Cadila, part of Cadila Healthcare group, said in a regulatory
filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-us-health-regulator-nod-for-multiple-sclerosis-treatment-drug/articleshow/78309972.cms
No comments:
Post a Comment